Powered by

HighLife Closes a (EURO)32 Million Round B Financing

Jan 17, 2019 - Business Wire
Investments

HighLife SAS, a medtech company focused on the development of a unique transcatheter mitral valve replacement ("TMVR") system to treat patients suffering from mitral regurgitation, announced today it had closed a (EURO)32 million round of equity financing.

Proceeds from the financing will be used to complete the development of the company's transcatheter transseptal mitral valve implantation program, which includes regulatory approval trials in Europe to obtain the CE mark and a first clin...